Pomerantz Law Firm Initiates Class Action Lawsuit Against Aardvark Therapeutics Over IPO Concerns

Pomerantz Law Firm Files Class Action Against Aardvark Therapeutics

On September 10, 2026, Pomerantz LLP announced the initiation of a class action lawsuit against Aardvark Therapeutics, Inc. (NASDAQ: AARD) along with certain officers and directors. This legal action has been filed in the United States District Court for the Southern District of California under the docket number 26-cv-04643. The case involves claims asserted by a group representing investors who purchased Aardvark's common stock aligned with the company's initial public offering (IPO) on February 13, 2025, and those who acquired securities during the defined Class Period, which extends until May 14, 2026.

Investors affected by this development are encouraged to communicate their interest in serving as Lead Plaintiff for the class by the deadline of October 13, 2026. Consultations concerning this action can be initiated via Danielle Peyton, reachable at [email protected] or 646-581-9980.

Aardvark Therapeutics is positioned as a clinical-stage biopharmaceutical entity dedicated to creating small-molecule therapies targeting metabolic disorders such as Prader-Willi Syndrome (PWS). This condition leads to uncontrollable hunger, identified as hyperphagia, impacting people's lives significantly. The company emphasizes that its product candidates are distinctive because they aim to inhibit the sensation of hunger rather than just suppress appetite. By focusing on Bitter Taste Receptors (TAS2Rs), Aardvark claims to activate physiological signals that help control hunger.

The primary focus of the lawsuit relates to Aardvark's lead product candidate, ARD-101, a small-molecule agonist designed to counteract hyperphagia. The research underpinning ARD-101 has been central to the company's strategy, culminating in a Phase 3 clinical trial named the Hunger Elimination or Reduction Objective (HERO) trial. Aardvark was optimistic, long before the initiation of this litigation, that ARD-101's development would yield positive results.

However, as is common in the biotechnology sector, the looming challenges emerged. In early 2025, Aardvark filed a registration statement with the Securities and Exchange Commission (SEC) in connection with its IPO. Initially met with enthusiasm, the stock's performance was later scrutinized when the company released troubling updates on its clinical trials, signaling potential safety issues.

In February 2026, Aardvark announced that it was voluntarily pausing the HERO trial due to concerning cardiac observations noted at higher-than-target therapeutic doses during safety assessments. This announcement sent shockwaves through the market, resulting in a sharp decline—56.2%—in Aardvark's stock price. Investors perceived this news as indicative of the product's potential flaws, prompting fears regarding the future of the therapy and its implications for the company's financial health.

Further complicating the situation, the U.S. Food and Drug Administration (FDA) subsequently imposed a full clinical hold on the investigational new drug application for ARD-101. This additional setback underscored the growing compilation of adverse information that had not been adequately disclosed to investors.

As of now, Aardvark's stock price has not rebounded to its IPO value, remaining significantly lower, suggesting that investors have faced considerable losses. The class action lawsuit aims to address these grievances, potentially holding Aardvark and its executives accountable for the alleged misrepresentations.

Pomerantz LLP is noted for its expertise in corporate and securities class litigation, having been established by recognized pioneer Abraham L. Pomerantz, who has played a significant role in advancing securities class actions. With a legacy extending over 85 years, Pomerantz continues to strive for justice on behalf of victims affected by corporate malpractice. This recent filing against Aardvark Therapeutics emphasizes the firm’s commitment to safeguarding the rights of investors.

For further details regarding participation in the class action or Aardvark's current status, interested parties should refer to Pomerantz's official website or reach out to the firm directly.